Skip to main content
NCBI home page
CMAJ : Canadian Medical Association Journal logoLink to CMAJ : Canadian Medical Association Journal
. 1989 Jun 1;140(11):1289–1299.

Guidelines for the use of intravenous thrombolytic agents in acute myocardial infarction. Ontario Medical Association Consensus Group on Thrombolytic Therapy.

C D Naylor 1, P W Armstrong 1
PMCID: PMC1269188  PMID: 2497946

Abstract

A consensus group convened under the auspices of the Ontario Medical Association produced guidelines for the use of intravenous thrombolytic agents in acute myocardial infarction. The guidelines, updated to December 1988, include the following points. 1) Any hospital that routinely accepts the responsibility for looking after patients with acute myocardial infarction could offer thrombolytic therapy if monitoring facilities are available and if the staff are experienced in the treatment of cardiac rhythm disturbances. 2) Before treatment, all patients must be carefully screened for factors predisposing to hemorrhagic complications. 3) A physician should be clearly designated as responsible for the care of the patient receiving an infusion and be available in the event of problems. 4) For the two approved agents the usual dosages are as follows: streptokinase, 1.5 million units given over 1 hour; and tissue-type plasminogen activator (tPA), 100 mg over 3 hours, delivered as 60 mg in the first hour (of which 6 to 7 mg should be given as a bolus in the first 1 to 2 minutes) and then an infusion of 20 mg/h over the next 2 hours. 5) Intravenous thrombolytics should be considered for any patient with presumed acute myocardial infarction, as suggested by prolonged chest pain or other appropriate symptoms and typical electrocardiographic changes. Expeditious treatment is critical, since myocardial necrosis occurs within hours. 6) Emergency angiography is indicated for patients with hemodynamic compromise and no apparent response to streptokinase or tPA and in those with recurrent chest pain suggestive of acute myocardial infarction despite an apparent response to intravenous thrombolysis. Angiography before discharge is recommended for patients with postinfarction angina or evidence from noninvasive testing of significant residual ischemic risk. 7) There is insufficient evidence to choose between streptokinase and tPA on the basis of the two most important outcome measures: patient survival and myocardial preservation. More conclusive evidence comparing tPA, streptokinase and another promising agent, acylated plasminogen-streptokinase activator complex, will be available in 1989-90.

Full text

PDF
1289

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Basinski A., Naylor C. D. Aspirin and fibrinolysis. Lancet. 1988 Nov 19;2(8621):1188–1189. doi: 10.1016/s0140-6736(88)90250-4. [DOI] [PubMed] [Google Scholar]
  2. Califf R. M., O'Neil W., Stack R. S., Aronson L., Mark D. B., Mantell S., George B. S., Candela R. J., Kereiakes D. J., Abbottsmith C. Failure of simple clinical measurements to predict perfusion status after intravenous thrombolysis. Ann Intern Med. 1988 May;108(5):658–662. doi: 10.7326/0003-4819-108-5-658. [DOI] [PubMed] [Google Scholar]
  3. Chesebro J. H., Knatterud G., Roberts R., Borer J., Cohen L. S., Dalen J., Dodge H. T., Francis C. K., Hillis D., Ludbrook P. Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge. Circulation. 1987 Jul;76(1):142–154. doi: 10.1161/01.cir.76.1.142. [DOI] [PubMed] [Google Scholar]
  4. Collen D., Topol E. J., Tiefenbrunn A. J., Gold H. K., Weisfeldt M. L., Sobel B. E., Leinbach R. C., Brinker J. A., Ludbrook P. A., Yasuda I. Coronary thrombolysis with recombinant human tissue-type plasminogen activator: a prospective, randomized, placebo-controlled trial. Circulation. 1984 Dec;70(6):1012–1017. doi: 10.1161/01.cir.70.6.1012. [DOI] [PubMed] [Google Scholar]
  5. Collins R., Peto R., Sleight P. Significant reduction in mortality with streptokinase given 7-24 hours after pain onset. Lancet. 1988 Nov 19;2(8621):1187–1188. doi: 10.1016/s0140-6736(88)90249-8. [DOI] [PubMed] [Google Scholar]
  6. Couper R., Bentur L., Durie P., Levison H. Microscopic nephrocalcinosis in cystic fibrosis. N Engl J Med. 1989 Feb 2;320(5):318–319. doi: 10.1056/NEJM198902023200516. [DOI] [PubMed] [Google Scholar]
  7. DeWood M. A., Spores J., Notske R., Mouser L. T., Burroughs R., Golden M. S., Lang H. T. Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. N Engl J Med. 1980 Oct 16;303(16):897–902. doi: 10.1056/NEJM198010163031601. [DOI] [PubMed] [Google Scholar]
  8. DeWood M. A., Stifter W. F., Simpson C. S., Spores J., Eugster G. S., Judge T. P., Hinnen M. L. Coronary arteriographic findings soon after non-Q-wave myocardial infarction. N Engl J Med. 1986 Aug 14;315(7):417–423. doi: 10.1056/NEJM198608143150703. [DOI] [PubMed] [Google Scholar]
  9. Ganz W., Geft I., Shah P. K., Lew A. S., Rodriguez L., Weiss T., Maddahi J., Berman D. S., Charuzi Y., Swan H. J. Intravenous streptokinase in evolving acute myocardial infarction. Am J Cardiol. 1984 May 1;53(9):1209–1216. doi: 10.1016/0002-9149(84)90066-3. [DOI] [PubMed] [Google Scholar]
  10. Gold H. K., Johns J. A., Leinbach R. C., Yasuda T., Collen D. Thrombolytic therapy for unstable angina pectoris: rationale and results. J Am Coll Cardiol. 1987 Nov;10(5 Suppl B):91B–95B. doi: 10.1016/s0735-1097(87)80433-3. [DOI] [PubMed] [Google Scholar]
  11. Gold H. K., Johns J. A., Leinbach R. C., Yasuda T., Grossbard E., Zusman R., Collen D. A randomized, blinded, placebo-controlled trial of recombinant human tissue-type plasminogen activator in patients with unstable angina pectoris. Circulation. 1987 Jun;75(6):1192–1199. doi: 10.1161/01.cir.75.6.1192. [DOI] [PubMed] [Google Scholar]
  12. Gold H. K., Leinbach R. C., Garabedian H. D., Yasuda T., Johns J. A., Grossbard E. B., Palacios I., Collen D. Acute coronary reocclusion after thrombolysis with recombinant human tissue-type plasminogen activator: prevention by a maintenance infusion. Circulation. 1986 Feb;73(2):347–352. doi: 10.1161/01.cir.73.2.347. [DOI] [PubMed] [Google Scholar]
  13. Guerci A. D., Gerstenblith G., Brinker J. A., Chandra N. C., Gottlieb S. O., Bahr R. D., Weiss J. L., Shapiro E. P., Flaherty J. T., Bush D. E. A randomized trial of intravenous tissue plasminogen activator for acute myocardial infarction with subsequent randomization to elective coronary angioplasty. N Engl J Med. 1987 Dec 24;317(26):1613–1618. doi: 10.1056/NEJM198712243172601. [DOI] [PubMed] [Google Scholar]
  14. Hennekens C. H., Peto R., Hutchison G. B., Doll R. An overview of the British and American aspirin studies. N Engl J Med. 1988 Apr 7;318(14):923–924. doi: 10.1056/NEJM198804073181412. [DOI] [PubMed] [Google Scholar]
  15. Hervé C., Gaillard M., Castaigne A., Jan F., Huguenard P. Thrombolysis at home. Lancet. 1987 Nov 28;2(8570):1278–1278. doi: 10.1016/s0140-6736(87)91891-5. [DOI] [PubMed] [Google Scholar]
  16. Hillis L. D., Borer J., Braunwald E., Chesebro J. H., Cohen L. S., Dalen J., Dodge H. T., Francis C. K., Knatterud G., Ludbrook P. High dose intravenous streptokinase for acute myocardial infarction: preliminary results of a multicenter trial. J Am Coll Cardiol. 1985 Nov;6(5):957–962. doi: 10.1016/s0735-1097(85)80294-1. [DOI] [PubMed] [Google Scholar]
  17. Johns J. A., Gold H. K., Leinbach R. C., Yasuda T., Gimple L. W., Werner W., Finkelstein D., Newell J., Ziskind A. A., Collen D. Prevention of coronary artery reocclusion and reduction in late coronary artery stenosis after thrombolytic therapy in patients with acute myocardial infarction. A randomized study of maintenance infusion of recombinant human tissue-type plasminogen activator. Circulation. 1988 Sep;78(3):546–556. doi: 10.1161/01.cir.78.3.546. [DOI] [PubMed] [Google Scholar]
  18. Koren G., Weiss A. T., Hasin Y., Appelbaum D., Welber S., Rozenman Y., Lotan C., Mosseri M., Sapoznikov D., Luria M. H. Prevention of myocardial damage in acute myocardial ischemia by early treatment with intravenous streptokinase. N Engl J Med. 1985 Nov 28;313(22):1384–1389. doi: 10.1056/NEJM198511283132204. [DOI] [PubMed] [Google Scholar]
  19. Laffel G. L., Fineberg H. V., Braunwald E. A cost-effectiveness model for coronary thrombolysis/reperfusion therapy. J Am Coll Cardiol. 1987 Nov;10(5 Suppl B):79B–90B. doi: 10.1016/s0735-1097(87)80432-1. [DOI] [PubMed] [Google Scholar]
  20. Lee L., Bates E. R., Pitt B., Walton J. A., Laufer N., O'Neill W. W. Percutaneous transluminal coronary angioplasty improves survival in acute myocardial infarction complicated by cardiogenic shock. Circulation. 1988 Dec;78(6):1345–1351. doi: 10.1161/01.cir.78.6.1345. [DOI] [PubMed] [Google Scholar]
  21. Lew A. S., Laramee P., Cercek B., Shah P. K., Ganz W. The hypotensive effect of intravenous streptokinase in patients with acute myocardial infarction. Circulation. 1985 Dec;72(6):1321–1326. doi: 10.1161/01.cir.72.6.1321. [DOI] [PubMed] [Google Scholar]
  22. Lurie Y., Mor F., Schoenfeld N., Leibovici L. Non-cardiac use of nitroglycerin patches. Eur Heart J. 1988 Feb;9(2):197–198. doi: 10.1093/oxfordjournals.eurheartj.a062479. [DOI] [PubMed] [Google Scholar]
  23. Marder V. J., Sherry S. Thrombolytic therapy: current status (1). N Engl J Med. 1988 Jun 9;318(23):1512–1520. doi: 10.1056/NEJM198806093182306. [DOI] [PubMed] [Google Scholar]
  24. Montague T. J., MacKenzie B. R., Henderson M. A., Macdonald R. G., Forbes C. J., Chandler B. M. Acute non-Q-wave myocardial infarction: a distinct clinical entity of increasing importance. CMAJ. 1988 Sep 15;139(6):487–493. [PMC free article] [PubMed] [Google Scholar]
  25. Mueller H. S., Rao A. K., Forman S. A. Thrombolysis in myocardial infarction (TIMI): comparative studies of coronary reperfusion and systemic fibrinogenolysis with two forms of recombinant tissue-type plasminogen activator. J Am Coll Cardiol. 1987 Sep;10(3):479–490. doi: 10.1016/s0735-1097(87)80188-2. [DOI] [PubMed] [Google Scholar]
  26. Naylor D., Linton A. L. Allocation of health care resources: a challenge for the medical profession. CMAJ. 1986 Feb 15;134(4):333–340. [PMC free article] [PubMed] [Google Scholar]
  27. O'Neill W. W., Topol E. J., Pitt B. Reperfusion therapy of acute myocardial infarction. Prog Cardiovasc Dis. 1988 Jan-Feb;30(4):235–266. doi: 10.1016/0033-0620(88)90018-7. [DOI] [PubMed] [Google Scholar]
  28. Patel B., Kloner R. A. Analysis of reported randomized trials of streptokinase therapy for acute myocardial infarction in the 1980s. Am J Cardiol. 1987 Mar 1;59(6):501–504. doi: 10.1016/0002-9149(87)91156-8. [DOI] [PubMed] [Google Scholar]
  29. Reimer K. A., Jennings R. B. The "wavefront phenomenon" of myocardial ischemic cell death. II. Transmural progression of necrosis within the framework of ischemic bed size (myocardium at risk) and collateral flow. Lab Invest. 1979 Jun;40(6):633–644. [PubMed] [Google Scholar]
  30. Reimer K. A., Lowe J. E., Rasmussen M. M., Jennings R. B. The wavefront phenomenon of ischemic cell death. 1. Myocardial infarct size vs duration of coronary occlusion in dogs. Circulation. 1977 Nov;56(5):786–794. doi: 10.1161/01.cir.56.5.786. [DOI] [PubMed] [Google Scholar]
  31. Ryan T. J. Angioplasty in acute myocardial infarction. Is the balloon leaking? N Engl J Med. 1987 Sep 3;317(10):624–626. doi: 10.1056/NEJM198709033171008. [DOI] [PubMed] [Google Scholar]
  32. Schwarz F., Schuler G., Katus H., Hofmann M., Manthey J., Tillmanns H., Mehmel H. C., Kübler W. Intracoronary thrombolysis in acute myocardial infarction: duration of ischemia as a major determinant of late results after recanalization. Am J Cardiol. 1982 Nov;50(5):933–937. doi: 10.1016/0002-9149(82)90398-8. [DOI] [PubMed] [Google Scholar]
  33. Sheehan F. H., Braunwald E., Canner P., Dodge H. T., Gore J., Van Natta P., Passamani E. R., Williams D. O., Zaret B. The effect of intravenous thrombolytic therapy on left ventricular function: a report on tissue-type plasminogen activator and streptokinase from the Thrombolysis in Myocardial Infarction (TIMI Phase I) trial. Circulation. 1987 Apr;75(4):817–829. doi: 10.1161/01.cir.75.4.817. [DOI] [PubMed] [Google Scholar]
  34. Simoons M. L., Arnold A. E., Betriu A., de Bono D. P., Col J., Dougherty F. C., von Essen R., Lambertz H., Lubsen J., Meier B. Thrombolysis with tissue plasminogen activator in acute myocardial infarction: no additional benefit from immediate percutaneous coronary angioplasty. Lancet. 1988 Jan 30;1(8579):197–203. doi: 10.1016/s0140-6736(88)91062-8. [DOI] [PubMed] [Google Scholar]
  35. Simoons M. L., Serruys P. W., vd Brand M., Bär F., de Zwaan C., Res J., Verheugt F. W., Krauss X. H., Remme W. J., Vermeer F. Improved survival after early thrombolysis in acute myocardial infarction. A randomised trial by the Interuniversity Cardiology Institute in The Netherlands. Lancet. 1985 Sep 14;2(8455):578–582. doi: 10.1016/s0140-6736(85)90584-7. [DOI] [PubMed] [Google Scholar]
  36. Steinberg E. P., Topol E. J., Sakin J. W., Kahane S. N., Appel L. J., Powe N. R., Anderson G. F., Erickson J. E., Guerci A. D. Cost and procedure implications of thrombolytic therapy for acute myocardial infarction. J Am Coll Cardiol. 1988 Dec;12(6 Suppl A):58A–68A. doi: 10.1016/0735-1097(88)92642-3. [DOI] [PubMed] [Google Scholar]
  37. Thrombolysis and angioplasty in acute myocardial infarction. N Engl J Med. 1988 Mar 3;318(9):576–579. doi: 10.1056/NEJM198803033180911. [DOI] [PubMed] [Google Scholar]
  38. Topol E. J., Bates E. R., Walton J. A., Jr, Baumann G., Wolfe S., Maino J., Bayer L., Gorman L., Kline E. M., O'Neill W. W. Community hospital administration of intravenous tissue plasminogen activator in acute myocardial infarction: improved timing, thrombolytic efficacy and ventricular function. J Am Coll Cardiol. 1987 Dec;10(6):1173–1177. doi: 10.1016/s0735-1097(87)80114-6. [DOI] [PubMed] [Google Scholar]
  39. Topol E. J. Coronary angioplasty for acute myocardial infarction. Ann Intern Med. 1988 Dec 15;109(12):970–980. doi: 10.7326/0003-4819-109-12-970. [DOI] [PubMed] [Google Scholar]
  40. Topol E. J., Morris D. C., Smalling R. W., Schumacher R. R., Taylor C. R., Nishikawa A., Liberman H. A., Collen D., Tufte M. E., Grossbard E. B. A multicenter, randomized, placebo-controlled trial of a new form of intravenous recombinant tissue-type plasminogen activator (activase) in acute myocardial infarction. J Am Coll Cardiol. 1987 Jun;9(6):1205–1213. doi: 10.1016/s0735-1097(87)80457-6. [DOI] [PubMed] [Google Scholar]
  41. Topol E. J., O'Neill W. W., Langburd A. B., Walton J. A., Jr, Bourdillon P. D., Bates E. R., Grines C. L., Schork A. M., Kline E., Pitt B. A randomized, placebo-controlled trial of intravenous recombinant tissue-type plasminogen activator and emergency coronary angioplasty in patients with acute myocardial infarction. Circulation. 1987 Feb;75(2):420–428. doi: 10.1161/01.cir.75.2.420. [DOI] [PubMed] [Google Scholar]
  42. Verstraete M., Arnold A. E., Brower R. W., Collen D., de Bono D. P., De Zwaan C., Erbel R., Hillis W. S., Lennane R. J., Lubsen J. Acute coronary thrombolysis with recombinant human tissue-type plasminogen activator: initial patency and influence of maintained infusion on reocclusion rate. Am J Cardiol. 1987 Aug 1;60(4):231–237. doi: 10.1016/0002-9149(87)90219-0. [DOI] [PubMed] [Google Scholar]
  43. Verstraete M., Bernard R., Bory M., Brower R. W., Collen D., de Bono D. P., Erbel R., Huhmann W., Lennane R. J., Lubsen J. Randomised trial of intravenous recombinant tissue-type plasminogen activator versus intravenous streptokinase in acute myocardial infarction. Report from the European Cooperative Study Group for Recombinant Tissue-type Plasminogen Activator. Lancet. 1985 Apr 13;1(8433):842–847. doi: 10.1016/s0140-6736(85)92208-1. [DOI] [PubMed] [Google Scholar]
  44. Verstraete M., Bleifeld W., Brower R. W., Charbonnier B., Collen D., de Bono D. P., Dunning A. J., Lennane R. J., Lubsen J., Mathey D. G. Double-blind randomised trial of intravenous tissue-type plasminogen activator versus placebo in acute myocardial infarction. Lancet. 1985 Nov 2;2(8462):965–969. doi: 10.1016/s0140-6736(85)90523-9. [DOI] [PubMed] [Google Scholar]
  45. White H. D., Norris R. M., Brown M. A., Takayama M., Maslowski A., Bass N. M., Ormiston J. A., Whitlock T. Effect of intravenous streptokinase on left ventricular function and early survival after acute myocardial infarction. N Engl J Med. 1987 Oct 1;317(14):850–855. doi: 10.1056/NEJM198710013171402. [DOI] [PubMed] [Google Scholar]
  46. Wilcox R. G., von der Lippe G., Olsson C. G., Jensen G., Skene A. M., Hampton J. R. Trial of tissue plasminogen activator for mortality reduction in acute myocardial infarction. Anglo-Scandinavian Study of Early Thrombolysis (ASSET). Lancet. 1988 Sep 3;2(8610):525–530. doi: 10.1016/s0140-6736(88)92656-6. [DOI] [PubMed] [Google Scholar]
  47. Yusuf S., Collins R., Peto R., Furberg C., Stampfer M. J., Goldhaber S. Z., Hennekens C. H. Intravenous and intracoronary fibrinolytic therapy in acute myocardial infarction: overview of results on mortality, reinfarction and side-effects from 33 randomized controlled trials. Eur Heart J. 1985 Jul;6(7):556–585. doi: 10.1093/oxfordjournals.eurheartj.a061905. [DOI] [PubMed] [Google Scholar]
  48. Yusuf S., Wittes J., Friedman L. Overview of results of randomized clinical trials in heart disease. I. Treatments following myocardial infarction. JAMA. 1988 Oct 14;260(14):2088–2093. [PubMed] [Google Scholar]
  49. de Bono D. P. Thrombolysis with intravenous human recombinant tissue-type plasminogen activator in acute myocardial infarction: the European experience. J Am Coll Cardiol. 1987 Nov;10(5 Suppl B):75B–78B. doi: 10.1016/s0735-1097(87)80431-x. [DOI] [PubMed] [Google Scholar]

Articles from CMAJ: Canadian Medical Association Journal are provided here courtesy of Canadian Medical Association

RESOURCES